Fampridine-SR ("4-aminopyridine", "4-AP", “fampridine”) is an investigational oral, sustained-release tablet formulation of 4-aminopyridine. In laboratory studies fampridine has been found to improve impulse conduction in nerve fibers in which the insulating layer, called myelin, has been damaged.

Clinical History of Fampridine-SR in Multiple Sclerosis (MS)

In June 2008, Acorda announced positive results from its second positive Phase 3 clinical trial of Fampridine-SR on walking ability in people with MS. For a copy of the press release and study results, please click here.

To learn about Fampridine-SR’s mechanism of action click here.